Prophylactic management of patients with von Willebrand disease

1. Rodeghiero, F, Castaman, G, Dini, E. Epidemiological investigation of the prevalence of von Willebrand disease. Blood 1987; 69: 454–459.
Google Scholar | Crossref | Medline | ISI2. Sadler, JE, Budde, U, Eikenboom, JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103–2114.
Google Scholar | Crossref | Medline | ISI3. James, PD, Connell, NT, Ameer, B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5: 280–300.
Google Scholar | Crossref | Medline4. Seidizadeh, O, Peyvandi, F, Mannucci, PM. Von Willebrand disease type 2N: an update. J Thromb Haemost 2021; 19: 909–916.
Google Scholar | Crossref | Medline5. Mannucci, PM . How I treat patients with von Willebrand disease. Blood 2001; 97: 1915–1919.
Google Scholar | Crossref | Medline6. Mannucci, PM, Franchini, M, Castaman, G, et al. Evidence based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117–126.
Google Scholar | Medline7. Connell, NT, Flood, VH, Brignardello-Petersen, R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5: 301–325.
Google Scholar | Crossref | Medline8. Mannucci, P . Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000; 6(Suppl. 1): 60–67.
Google Scholar | Crossref | Medline | ISI9. Franchini, M, Mannucci, PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol 2016; 9: 825–830.
Google Scholar | Crossref | Medline10. Mannucci, PM. Hemostatic drugs. N Engl J Med 1998; 339: 245–253.
Google Scholar | Crossref | Medline | ISI11. Mannucci, PM . New therapies for von Willebrand disease. Blood Adv 2019; 3: 3481–3487.
Google Scholar | Crossref | Medline12. Miesbach, W, Berntorp, E. Translating the success of prophylaxis in haemophilia to von Willebrand disease. Thromb Res 2021; 199: 67–74.
Google Scholar | Crossref | Medline13. van Galen, KP, Sanders, YV, Vojinovic, U, et al. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia 2015; 21: e185–e192.
Google Scholar | Crossref | Medline14. Chornenki, NL, Shanjer, M, James, PD. Vascular abnormalities in patients with von Willebrand disease: a scoping review. J Thromb Haemost 2021; 19: 2151–2160.
Google Scholar | Crossref | Medline15. Connell, NT, James, PD, Brignardello-Petersen, R, et al. von Willebrand disease: proposing definitions for future research. Blood Adv 2021; 5: 565–569.
Google Scholar | Medline16. Castaman, G, Lethagen, S, Federici, AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111: 3531–3539.
Google Scholar | Crossref | Medline | ISI17. Federici, AB, Mazurier, C, Berntorp, E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 2032–2038.
Google Scholar | Crossref | Medline | ISI18. Berntorp, E, Archey, W, Auerswald, G, et al. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate® P/Humate®-P: history and clinical performance. Eur J Haematol 2008; 80: 3–35.
Google Scholar | Crossref19. Thompson, AR, Gill, JC, Ewenstein, B, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®). Haemophilia 2004; 10: 42–51.
Google Scholar | Crossref | Medline20. Lethagen, S, Kyrle, P, Castaman, G, et al. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420–1430.
Google Scholar | Crossref | Medline21. Gill, J, Shapiro, A, Valentino, L, et al. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Haemophilia 2011; 17: 895–905.
Google Scholar | Crossref | Medline | ISI22. Lillicrap, D, Poon, M-C, Walker, I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224–230.
Google Scholar | Crossref | Medline23. Franchini, M, Rossetti, G, Tagliaferri, A, et al. Efficacy and safety of factor VIII/von Willebrand’s factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88: 1279–1283.
Google Scholar | Medline24. Federici, AB, Castaman, G, Franchini, M, et al. Clinical use of Haemate® P in inherited von Willebrand’s disease: a cohort study on 100 Italian patients. Haematologica 2007; 92: 944–951.
Google Scholar | Crossref | Medline25. Castaman, G, Coppola, A, Zanon, E, et al. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease. Haemophilia 2013; 19: 82–88.
Google Scholar | Crossref | Medline26. Mannuccio Mannucci, P, Kyrle, PA, Schulman, S, et al. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand’s disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfus 2013; 11: 533–540.
Google Scholar | Medline27. Mannucci, PM, Chediak, J, Hanna, W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Presented in part at the meeting of the International Society of Thrombosis and Haemostasis in Washington, DC, . Blood 2002; 99: 450–456.
Google Scholar | Crossref28. Rivard, G, Aledort, L, Investigators, AS. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate® in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008; 14: 271–275.
Google Scholar | Crossref | Medline29. Federici, A, Baudo, F, Caracciolo, C, et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002; 8: 761–767.
Google Scholar | Crossref | Medline30. Federici, A, Barillari, G, Zanon, E, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia 2010; 16: 101–110.
Google Scholar | Crossref | Medline31. Windyga, J, von Depka-Prondzinski, M and European Wilate® Study Group . Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072–1079.
Google Scholar | Crossref | Medline32. Srivastava, A, Serban, M, Werner, S, et al. Efficacy and safety of a VWF/FVIII concentrate (Wilate®) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia 2017; 23: 264–272.
Google Scholar | Crossref | Medline33. Batty, P, Chen, YH, Bowles, L, et al. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience. Haemophilia 2014; 20: 846–853.
Google Scholar | Crossref | Medline34. Shortt, J, Dunkley, S, Rickard, K, et al. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate®) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia 2007; 13: 144–148.
Google Scholar | Crossref | Medline35. Dunkley, S, Baker, R, Pidcock, M, et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE® in patients with von Willebrand’s disease: a prospective multi-centre study. Haemophilia 2010; 16: 615–624.
Google Scholar | Medline36. Borel-Derlon, A, Federici, A, Roussel-Robert, V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115–1124.
Google Scholar | Crossref | Medline37. Goudemand, J, Bridey, F, Claeyssens, S, et al. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: results from a prospective observational post-marketing study. J Thromb Haemost 2020; 18: 1922–1933.
Google Scholar | Crossref | Medline38. Mannucci, PM, Franchini, M. Von Willebrand’s disease. N Engl J Med 2017; 376: 701.
Google Scholar | Crossref | Medline39. Koster, T, Vandenbroucke, J, Rosendaal, F, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152–155.
Google Scholar | Crossref | Medline | ISI40. Makris, M, Colvin, B, Gupta, V, et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 2002; 88: 387–388.
Google Scholar | Crossref | Medline | ISI41. Coppola, A, Franchini, M, Makris, M, et al. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18: e173–e187.
Google Scholar | Crossref | Medline | ISI42. Mannucci, P . Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378–379.
Google Scholar | Crossref | Medline43. Lubetsky, A, Schulman, S, Varon, D, et al. Safety and efficacy of continuous infusion of a combined factor VIII–von Willebrand factor (vWF) concentrate (Haemate-P™) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 229–233.
Google Scholar | Crossref | Medline | ISI44. Mannucci, PM, Kempton, C, Millar, C, et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 2013; 122: 648–657.
Google Scholar | Crossref | Medline | ISI45. Gill, JC, Castaman, G, Windyga, J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015; 126: 2038–2046.
Google Scholar | Crossref | Medline | ISI46. Peyvandi, F, Mamaev, A, Wang, JD, et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost 2019; 17: 52–62.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif